Our portfolio company Eternygen GmbH will be present at BIO-Europe in Hamburg from 11th to 13th of November at Hamburg Messe. Eternygen will be represented by its Head of Research Dr. Grit Zahn and by its Managing Director Marco Janezic. The team looks forward to meeting investors and potential cooperation partners to drive their scientific process forward. Feel free to get in touch with us, if you would like to schedule a meeting!
ABOUT ETERNYGEN GMBH
Eternygen is a Berlin, Germany based Biotech Company founded in June 2012 to focus on the research, development and marketing of NaCT inhibitors for the treatment of dietary-related metabolic diseases. The founding team consists of renowned scientists from leading German universities and academic institutes as well as serial entrepreneurs from the venture and industry community. Eternygen is a virtual company supported by a network of senior industry experts and contract research organizations. Eternygen shareholders include Epidarex Capital, Evotec AG, VC Fonds Technologie, Berlin, Germany managed by IBB Beteiligungsgesellschaft mbH, and two renowned family offices. For additional information please go to www.eternygen.com.